|
Volumn 12, Issue 3, 2009, Pages 165-168
|
Novel therapeutic strategies in prostate cancer: Establishing a stratification system for patient selection in targeted trials
|
Author keywords
Clinical trial; Molecular target; Personalized therapy; Prostate cancer
|
Indexed keywords
ABIRATERONE;
BEVACIZUMAB;
BEZ 235;
BICALUTAMIDE;
CARBON 11;
DOCETAXEL;
ERLOTINIB;
EVEROLIMUS;
GEFITINIB;
MAMMALIAN TARGET OF RAPAMYCIN;
MDV 3100;
MOLECULAR MARKER;
PANOBINOSTAT;
PHOSPHATIDYLINOSITOL 3 KINASE;
PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;
PREDNISONE;
TANESPIMYCIN;
TESTOSTERONE;
TETRAHYDROLIPSTATIN;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
VORINOSTAT;
XL 765;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL EVALUATION;
CLINICAL TRIAL;
GENOMICS;
HISTOPATHOLOGY;
HUMAN;
IN VIVO STUDY;
LUNG CANCER;
MONOTHERAPY;
POSITRON EMISSION TOMOGRAPHY;
PROSTATE CANCER;
PROTEOMICS;
REVIEW;
TESTOSTERONE BLOOD LEVEL;
TUMOR BIOPSY;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
HUMANS;
MALE;
PATIENT SELECTION;
PROSTATIC NEOPLASMS;
|
EID: 62249192007
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (3)
|
References (4)
|